Related Experiment Video
Updated: Mar 23, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Serelaxin for the treatment of heart failure
Danyaal S Moin1, Michelle W Bloom1, Lampros Papadimitriou1
1a Division of Cardiology , Stony Brook University School of Medicine , Stony Brook , NY , USA.
Abstract:
Outcomes for patients with acute heart failure remain suboptimal and treatments principally target improvement of symptoms. To date there has been no therapy approved for acute heart failure shown to improve mortality or readmission risk post-discharge. Serelaxin, a recombinant form of the naturally occurring polypeptide hormone relaxin, has demonstrated promise in preclinical and early clinical trials as a potentially novel therapy for acute heart failure. It is postulated through its anti-fibrotic and vasodilatory effects that this agent can improve outcomes in both the short and long term in these patients. Randomized clinical data has suggested that the medication is safe and well tolerated. However, definitive outcomes data is currently being assessed in a large multi-center trial.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Skeletal Muscle Relaxants: Therapeutic Uses
Heart Failure V: Medical Management
Heart Failure Drugs: Inotropic Agents
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

